Circulating microRNAs as Novel Prognosis Biomarkers for Rheumatoid Arthritis

Rh Disease Clinical Trial

Official title:

Circulating microRNAs Expression as Predictors of Clinical Response in Rheumatoid Arthritis Patients Treated With Green Tea

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03719469
• Other study ID #: RRC-2015-058
• Status: Completed
• Start date: January 20, 2015
• Est. completion date: September 20, 2015

Study information

• Verified date: October 2018
• Source: King Saud University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The correlation of circulating serum miR-125ba and miR-146a expression and clinical response to green tea therapy were analysed in RA patients.Clinical response to green tea therapy for 24 weeks was calculated from DAS28 scores. Whereas , a decrease of 1.2 points or above in DAS28 scores at 24 weeks of treatment compared with baseline was defined as clinical response according to the EULAR response criteria.A ready-made solutions containing the primers and probes for human miR-146a and miR-125ba (Applied Biosystems, Foster City, CA) and real-time RT-PCR was estimated using an ABI 7300 system (Applied Bio systems).

Description:

1. participants: A total of 100 subjects (aged 18-65 years) who were diagnosed as RA with moderate to severe activity at the division of rheumatology and clinical immunology at Mansoura University were evaluated in this study.

2. patients were evaluated for therapeutic response at baseline and 12, and 24 weeks of green tea therapy. All patients with RA were subjected for estimation of ESR, CRP, disease activity score in 28 joints (DAS28), patient's global assessment (PGA), and health assessment questionnaire damage index (HAQ-DI) at each visits (0 week, 12 weeks, and 24 weeks).

3. Pain intensity was assessed by using a standard VAS of 100 mm previously validated to chronic and acute pains.

4. Clinical response to green tea therapy for 24 weeks was calculated from DAS28 scores.

5. human miR-146a and miR-125ba were isolated and subjected to RT-PCR analysis

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: September 20, 2015
• Est. primary completion date: January 20, 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• subjects (aged 18-65 years) who were diagnosed as RA with moderate to severe activity at the division of rheumatology and clinical immunology at Mansoura University, between 20 January/2015 and 20 September 2015 were recruited in this prospective study.

• According to the diagnostic criteria of the American College of Rheumatology (Arnett et al., 1988), all patients classified as showing established RA for more than 8 years.

• Only patients who had higher scores of DAS28-ESR, RA biomarkers, and established radiographic analysis, and were diagnosed with RA according to the 2010ACR/ EULAR classification criteria were included in this study.

Exclusion Criteria:

• Patients who received non-steroidal anti-inflammatory drugs, oral glucocorticoids, had a history of severe deformation of joint, pregnant or lactating women were excluded from this study.

Related Conditions & MeSH terms

• Arthritis, Rheumatoid
• Rh Disease

Intervention

Dietary Supplement:
• Green tea group

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
King Saud University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Functional status	It will be assessed using disease activity score -28 (DAS28) and pre-validated health assessment questionnaire damage index (HAQ-DI). For DAS28 score, the number of swelling joints count (SJC) (0-28) and tender joints count (TJC) (0-28) in all patients were examined and DAS28 scores were calculated . DAS28 values > 2.6 and = 3.2 was considered as low RA disease activity, values > 3.2 and = 5.1 was considered as moderate disease activity and those > 5.1 was considered as high disease activity. In case of HAQ-DI, score calculation involves answering of eight domains(dressing, rising, eating, walking, hygiene, grip, reach and usual activities) with four point likert scale . SDAI values > 3.3 and =11 was considered as low RA disease activity, values > 11 and = 26 was considered as moderate disease activity and those > 26 was considered as high disease activity	change from baseline functional status at 24 weeks
Secondary	Pain intensity	It will be assessed using the visual analogue scale (VAS). The patients were asked to mark on the VAS scale of 0-10 cm according to their global assessment of pain. The physician marked on the VAS of 0-10 cm according to the physician global assessment. Patients with higher VAS scores were considered with greater pain intensity.	change from baseline functional status at 24 weeks
Secondary	Abnormal cell physiology and the parthenogenesis of Rheumatoid arthritis (RA)	it will be assessed by estimating the role of micro ribonucleic acid (microRNAs) in maintaining immune and inflammatory responses. In this part, the expression of miRNAs was estimated by real-time polymerase chain reaction (RT-PCR) analysis, whereas serum samples of each patients were subjected to PCR analysis. Patients with higher miRNAs expressionshowed greater abnormal in cell physiology and the pathogenesis of RH. Whereas normal subjects (= 1.2), and abnormal subjects ( ? 1.2)	change from baseline functional status at 24 weeks